Evidence map›Paper›PMID 19478057›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2009

Gag- and Nef-specific CD4+ T cells recognize and inhibit SIV replication in infected macrophages early after infection.

Jonah B Sacha, Juan P Giraldo-Vela, Matthew B Buechler, Mauricio A Martins, Nicholas J Maness, Chungwon Chung, Lyle T Wallace, Enrique J León, Thomas C Friedrich, Nancy A Wilson and 2 more

Abstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers.

0numbers the graph read from it
0cells of the map it votes in
59citing papers in PubMed
4.6field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

59 citing papers in PubMed, 94 citations in OpenAlex.

  1. Antiretroviral therapy blocks natural selection on protective and disease-susceptible HLA-B alleles in HIV-1 infection.Proceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  2. Cytotoxic CD4Signal transduction and targeted therapy · 2026
    Review
  3. Cytotoxic CD4Frontiers in immunology · 2023
    Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Frontiers in immunology · 2018
    Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 2 countries.

Jonah B SachaDepartment of Pathology and Laboratory Medicine, University of Wisconsin, Madison, WI 53715, USA. jbsacha@wisc.edu
Juan P Giraldo-Vela
Matthew B Buechler
Mauricio A Martins
Nicholas J Maness
Chungwon Chung
Lyle T Wallace
Enrique J León
Thomas C Friedrich
Nancy A Wilson
Atsunobu Hiraoka
David I Watkins
National Cancer Institute · USOsaka Dental University · JPUniversity of Wisconsin–Madison · US

Funding

ZOLEDRONATE PREVENTS BONE LOSS IN OVARIECTOMIZED RHESUS MONKEYSP51RR000167 · NCRR · UNIVERSITY OF WISCONSIN-MADISON · PI WATKINS, DAVID I · 1985 to 2011
$106.7M
A NOVEL, LOGICAL APPROACH TO HIV VACCINE DEVELOPMENTR01AI049120 · NIAID · UNIVERSITY OF WISCONSIN-MADISON · PI WATKINS, DAVID I · 2001 to 2009
$7.6M
EXTRAMURAL RES FACIL CONST: REPRODUCTIVE, GROWTH &DVMT, MENOPAUSEC06RR020141 · NCRR · UNIVERSITY OF WISCONSIN MADISON · PI CADWALLADER, MARTIN · 2004 to 2004
$3.6M
Minigene Vaccination with Early Presented Viral ProteinsR01AI076114 · NIAID · UNIVERSITY OF WISCONSIN-MADISON · PI RAKASZ, EVA GIZELLA · 2007 to 2011
$3.3M
EXTRAMURAL REGIONAL FACILITIES CONSTRUCTIONC06RR015459 · NCRR · UNIVERSITY OF WISCONSIN MADISON · PI CADWALLADER, MARTIN · 2000 to 2000
$1.9M
Correlates of elite control of SIVR21AI068586 · NIAID · UNIVERSITY OF WISCONSIN-MADISON · PI FRIEDRICH, THOMAS C. · 2006 to 2007
$506k
NCRR NIH HHS C06 RR015459NCRR NIH HHS C06 RR020141NCRR NIH HHS P51 RR000167NCRR NIH HHS RR020141-01NCRR NIH HHS RR15459-01NIAID NIH HHS R01 AI049120NIAID NIH HHS R01 AI076114NIAID NIH HHS R21 AI068586
6 · The paper itself

Abstract

The precise immunological role played by CD4(+) T cells in retroviral infections is poorly defined. Here, we describe a new function of these cells, the elimination of retrovirus-infected macrophages. After experimental CD8(+) cell depletion, elite controlling macaques with set-point viral loads < or = 500 viral RNA copies/mL mounted robust Gag- and Nef-specific CD4(+) T cell responses during reestablishment of control with > or = 54% of all virus-specific CD4(+) T cells targeting these 2 proteins. Ex vivo, these simian immunodeficiency virus (SIV)-specific CD4(+) T cells neither recognized nor suppressed viral replication in SIV-infected CD4(+) T cells. In contrast, they recognized SIV-infected macrophages as early as 2 h postinfection because of presentation of epitopes derived from virion-associated Gag and Nef proteins. Furthermore, virus-specific CD4(+) T cells displayed direct effector function and eliminated SIV-infected macrophages. These results suggest that retrovirus-specific CD4(+) T cells may contribute directly to elite control by inhibiting viral replication in macrophages.

Indexed as

AnimalsCD4-Positive T-LymphocytesGene Products, gagGene Products, nefMacaca mulattaMacrophagesRNA, ViralSimian Acquired Immunodeficiency SyndromeSimian Immunodeficiency VirusViral LoadVirus ReplicationGene Products, gagGene Products, nefRNA, Viral

Identifiers

PMID19478057
PMCPMC2687996
OpenAlexW2151050278

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.